BioLife Solutions, Inc. (BLFS)

NASDAQ: BLFS · IEX Real-Time Price · USD
24.43
-1.59 (-6.11%)
At close: Feb 7, 2023, 4:00 PM
24.92
+0.49 (2.01%)
After-hours: Feb 7, 2023, 5:34 PM EST
-6.11%
Market Cap 1.04B
Revenue (ttm) 154.81M
Net Income (ttm) -103.83M
Shares Out 42.77M
EPS (ttm) -2.48
PE Ratio n/a
Forward PE 625.00
Dividend n/a
Ex-Dividend Date n/a
Volume 266,115
Open 25.82
Previous Close 26.02
Day's Range 23.75 - 26.30
52-Week Range 10.40 - 29.92
Beta 1.81
Analysts Buy
Price Target 31.62 (+29.43%)
Earnings Date Feb 27, 2023

About BLFS

BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line ... [Read more]

Sector Healthcare
IPO Date Nov 22, 1989
Employees 432
Stock Exchange NASDAQ
Ticker Symbol BLFS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 15 analysts, the average rating for BLFS stock is "Buy." The 12-month stock price forecast is $31.62, which is an increase of 29.43% from the latest price.

Price Target
$31.62
(29.43% upside)
Analyst Consensus: Buy
Stock Forecasts

News

BioLife Solutions Announces 2023 Analyst Day & Participation in Upcoming Investor Conferences

BOTHELL, Wash. , Jan. 17, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and servic...

3 weeks ago - PRNewsWire

BioLife Solutions Announces 2022 Fourth Quarter and Full Year Preliminary Unaudited Revenue and Introduces 2023 Revenue Guidance

Record quarterly revenue of $44.4 million up 19% over Q4 2021 with Cell Processing Platform revenue growth of 37% Record full year revenue of $161.9 million up 36% over 2021, with organic revenue grow...

1 month ago - PRNewsWire

BioLife Solutions to Announce Preliminary 2022 Revenue and Introduce 2023 Revenue Guidance on January 9, 2023

Announcement Precedes Meetings to be Held During the J.P. Morgan Health Care Conference; Updated Investor Presentation Demonstrates Continued Execution to Drive High-Margin, Recurring Revenue BOTHELL,...

1 month ago - PRNewsWire

BioLife Solutions Expands Intellectual Property Estate

7 New Granted Patents; 43 Submitted Patent Applications Global Portfolio Now Totals 148 Issued and 114 Pending Patents BOTHELL, Wash. , Nov. 21, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: B...

2 months ago - PRNewsWire

BioLife Solutions Named in BioSpace Best Places to Work in Biopharma 2023 Report

Only 60 Companies Selected – Based on 2,000 Respondents BOTHELL, Wash. , Nov. 17, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supp...

2 months ago - PRNewsWire

BioLife Solutions, Inc. (BLFS) Reports Q3 Loss, Lags Revenue Estimates

BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -27.78% and 2.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the s...

3 months ago - Zacks Investment Research

BioLife Solutions Reports Third Quarter 2022 Financial Results

Record revenue of $40.7 million increased 21% over Q3 2021; biopreservation media revenue growth of 50%, validating leading position as a critical cell and gene therapies tool supplier Cash flow from ...

3 months ago - PRNewsWire

BioLife Solutions to Report Third Quarter 2022 Financial Results and Provide Business Update on November 9, 2022

BOTHELL, Wash. , Nov. 2, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and ...

3 months ago - PRNewsWire

CSafe and BioLife Solutions, Inc. announce partnership to expand supply chain solutions for the cell and gene therapy market

CSafe joins BioLife's global partner network of cold chain solution providers using the evo® cold chain management platform MONROE, Ohio and BOTHELL, Wash. , Oct. 11, 2022 /PRNewswire/ -- CSafe, one o...

4 months ago - PRNewsWire

BioLife Solutions Announces COO to Retire and Join Board of Directors

Roderick de Greef retirement planned for January 2023 with appointment to  BioLife Board of Directors Geraint Phillips to assume responsibilities in January 2023 as newly promoted Senior Vice Presiden...

4 months ago - PRNewsWire

BioLife Solutions Appoints Cell Therapy Executive Timothy L. Moore to its Board of Directors

Industry veteran brings extensive technical operations scale-up experience and extreme fluency in cell therapy tools and services selection process BOTHELL, Wash. , Aug. 25, 2022 /PRNewswire/ --  BioL...

5 months ago - PRNewsWire

BioLife Solutions, Inc. (BLFS) Reports Q2 Loss, Tops Revenue Estimates

BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -755% and 3.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

BioLife Solutions Reports Second Quarter 2022 Financial Results and Updates Full Year 2022 Revenue Guidance

Record revenue of $40.5 million increased 30% over Q2 2021, with organic revenue growth of 44% and biopreservation media revenue growth of 46% Updating 2022 revenue guidance to $160 million to $166 mi...

6 months ago - PRNewsWire

BioLife Solutions to Report Second Quarter 2022 Financial Results and Provide Business Update on August 9, 2022

BOTHELL, Wash., Aug. 2, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and b...

6 months ago - PRNewsWire

BioLife Solutions Deploys SciSafe's Ultra Low Controlled Temperature Trailers to Extend Domestic Cold Chain Services

The new service will enable life sciences companies to seamlessly move hardware as well as biomaterials at the local level BOTHELL, Wash. , June 9, 2022 /PRNewswire/ -- BioLife Solutions, Inc.

8 months ago - PRNewsWire

BioLife Solutions, Inc. (BLFS) Reports Q1 Loss, Lags Revenue Estimates

BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of 29.17% and 4.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

BioLife Solutions Reports First Quarter 2022 Financial Results

Revenue of $36.2 million increased 115% over Q1 2021, with organic revenue growth of 45% and biopreservation media revenue growth of 53% Affirms 2022 revenue guidance of $159.5 million to $171.0 milli...

9 months ago - PRNewsWire

BioLife Solutions Executes Co-Marketing Agreement with Coriell Institute for Medical Research to Offer Biostorage, Biospecimen Processing and Custom Laboratory Services

BOTHELL, Wash. , May 9, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and b...

9 months ago - PRNewsWire

BioLife Solutions to Report First Quarter 2022 Financial Results and Provide Business Update on May 9, 2022

BOTHELL, Wash. , May 2, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and b...

10 months ago - PRNewsWire

New Strong Sell Stocks for May 2nd

ALEC, AMRS, and BLFS have been added to the Zacks Rank #5 (Strong Sell) List on May 2, 2022

Other symbols: ALECAMRS
10 months ago - Zacks Investment Research

BioLife Solutions, Inc. Announces Change of Auditor to Grant Thornton LLP

BOTHELL, Wash. , April 7, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and servic...

10 months ago - PRNewsWire

New Strong Sell Stocks for March 31st

BLFS, CRNT, and AMBA have been added to the Zacks Rank #5 (Strong Sell) List on March 31, 2022.

Other symbols: AMBACRNT
11 months ago - Zacks Investment Research

BioLife Solutions Receives Nasdaq Notice of Noncompliance for Delayed 10-K Filing

BOTHELL, Wash. , March 18, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and servi...

11 months ago - PRNewsWire

BioLife Solutions Announces Additional Delay in Filing of Annual Report on Form 10-K

BOTHELL, Wash., March 17, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and servic...

11 months ago - PRNewsWire

BioLife Solutions Secures Strategic Customer Wins and Plans 2022 Expansion in $400 Million Biostorage Services Market

BOTHELL, Wash. , March 15, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") an...

11 months ago - PRNewsWire